Artivion, Inc. (AORT) - Stock Analysis
Last updated: Jun 27, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fresh medical-device catalyst with improving operations: AORT received FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 after prior NEXUS Aortic Arch approval on 2026-04-07 and Endospan acquisition completion on 2026-05-18; Q1 2026 revenue rose 18% YoY to $116.3M and adjusted EBITDA rose 26% to $22.1M.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Thin margins ⢠High valuation AORT has strong liquidity and gross margins, but weak profitability, uneven cash flow, meaningful interest burden, and an expensive valuation make the stock look risky.
Price Behavior
Key Price Behavior Insights: ⢠Sharp Reversal ⢠Resistance Reclaim ⢠Fragile Base Support Level: $20.10-$20.60 Resistance Level: $23.61-$23.76 AORT rebounded sharply from near $20.13 to $23.61 over the last month, reclaiming the $22.00-$22.70 resistance zone and turning short-term momentum constructive, but it remains fragile until it holds above $20.10-$20.60 and clears $23.61-$23.76.
Sentiment & News
Key News Insights: ⢠Conference presence ⢠Fireside chat ⢠No new guidance Artivion will participate in the 2026 Truist Securities MedTech Conference with a scheduled fireside chat, signaling ongoing investor engagement but no new operational or financial updates.
AI Summary
AORT is shifting from a niche device story to a broader aortic platform with NEXUS and Endospan, making the investment case more compelling, but the stock should be judged on whether this growth can translate into durable free cash flow rather than just higher revenue, with integration and regulatory overhangs as the main risks.
Description
Artivion Inc. develops, manufactures and distributes medical devices and implantable human tissues for cardiac, vascular, thoracic and general surgical procedures worldwide. Its portfolio combines biologic materials, synthetic vascular grafts, surgical sealants, hemostatic agents, prosthetic heart valves and a range of endovascular stent graft systems and preservation and coating services for device makers. The company serves hospitals and surgeons, was founded in 1984, and changed its name from CryoLife, Inc. to Artivion Inc. in January 2022, with headquarters in Kennesaw, Georgia.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 29 | Jul 6 | AORT | Artivion, Inc. | Fresh medical-device catalyst with improving operations: AORT received FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 after prior NEXUS Aortic Arch approval on 2026-04-07 and Endospan acquisition completion on 2026-05-18; Q1 2026 revenue rose 18% YoY to $116.3M and adjusted EBITDA rose 26% to $22.1M. | Active | +0.0% |